Skip to Main Content
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Inside the Corner Office
    • Rising Stars Network
    • Celebrating 100 Years
      • New England Council Fellows Program
    • Sponsorship Opportunities
  • Contact
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Inside the Corner Office
    • Rising Stars Network
    • Celebrating 100 Years
      • New England Council Fellows Program
    • Sponsorship Opportunities
  • Contact

News

Feb 6, 2025Blog | Member News, Healthcare

FDA approves Vertex Pharmaceuticals’ new non-opioid painkiller

Boston Globe

New England Council member, Vertex Pharmaceuticals, announced that Journavx, a non-opioid painkiller, has been approved by the U.S. Food and Drug Administration (FDA). The biotech company has invested in developing a non-opioid pain medicine for over 20 years, aiming to address the nation’s opioid crisis and offer a pain relief option without the risk of addiction.

The FDA approved the pill to treat adults with moderate-to-severe acute pain. It works by blocking pain signals only found in the peripheral pain-sensing neurons, not in the brain, thus providing effective pain relief without the addictive potential of opioids. As this is a prescription medicine, patients should always go to their healthcare provider for medical advice about treatments first. Vertex has established patient support programs to help ensure that patients can access information and consultation about Journavx.

“Today’s approval is a historic milestone for the 80 million people in America who are prescribed a medicine for moderate-to-severe acute pain each year,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “With the approval of Journavx, . . . we have the opportunity to change the paradigm of acute pain management and establish a new standard of care.”

The New England Council commends Vertex Pharmaceuticals for this important milestone for public health.

Read more via the Boston Globe and Vertex Press.

Council Related News
Read Article Blog | Member News, Financial Services

Citizens Bank announces new program: “Citizens for Startups”

Read Article Blog | Member News, Higher Education

Brown University names new dean of the College

Read Article Blog | Member News, Healthcare

Waters Corporation acquires specialized imaging technology from Halo Labs

Read Article Blog | Member News, Healthcare

Sanofi to acquire Vigil Neuroscience, Inc. for $470M

Read Article Blog | Member News, Technology & Innovation

Pitney Bowes appoints new CEO

View Related News

©2025 New England Council
All rights reserved.

Privacy Policy Website Design by Jackrabbit

Boston Office

98 North Washington Street
Suite 303
Boston, MA 02114

(617) 723-4009

necouncil@newenglandcouncil.com

Washington Office

1411 K Street, NW
Suite 700
Washington, D.C. 20005

(202) 547-0048

necouncil@newenglandcouncil.com

Website Design by Jackrabbit